Probatebeta
Target

FLT3

Receptor-type tyrosine-protein kinase FLT3

As of the edition of 20 October 2026, FLT3 (receptor-type tyrosine-protein kinase FLT3, UniProt P36888) has 42 drugs tested at it and 44 companies on the list, 25 on route A and 6 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P36888
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
11
Disease areas
Cancer; Digestive system; Blood and lymph; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Lungs and airways; Hormones
Registered trials of its drugs
1,621

Drugs at this target

StatusCount
Marketed8
Active7
Went quiet10
Stopped15
Status not established2
Total42
DrugStatusFurthest phaseUS protection
SorafenibMarketedPhase 4Ends 2027
SunitinibMarketedPhase 4none listed
GilteritinibMarketedPhase 3Ends 2032
FamitinibStoppedPhase 3none listed
DovitinibActivePhase 3none listed
PacritinibMarketedPhase 3Ends 2030
MidostaurinMarketedPhase 3none listed
QuizartinibMarketedPhase 3Ends 2030
SitravatinibStoppedPhase 3none listed
FedratinibMarketedPhase 3Ends 2031
PexidartinibMarketedPhase 4Ends 2036
CrenolanibStoppedPhase 3none listed

12 of 42 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A25
Route B6
Engaged8
Undetermined5
Total on the list44
Three companies on route A or B, with the route only
CompanyRoute
PfizerRoute B
NovartisRoute B
Jiangsu HengRui MedicineRoute A

The other 41 companies at FLT3

In the product

44 companies in all; 41 are not named here, and no score is.

See the 44 companies at FLT3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at FLT3

Other targets in cancer

Companies holding approvals at FLT3